• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).

作者信息

Rule Simon A, Cartron Guillaume, Fegan Christopher, Morschhauser Franck, Han Lingling, Mitra Siddhartha, Salles Gilles, Dyer Martin J S

机构信息

Department of Clinical Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK.

Department of Clinical Hematology and Unité Mixte de Recherche-Centre National de la Recherche Scientifique 5235, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France.

出版信息

Leukemia. 2020 May;34(5):1458-1461. doi: 10.1038/s41375-019-0658-7. Epub 2019 Dec 11.

DOI:10.1038/s41375-019-0658-7
PMID:31827243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7192842/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/176c/7192842/0d67da749f75/41375_2019_658_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/176c/7192842/0d67da749f75/41375_2019_658_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/176c/7192842/0d67da749f75/41375_2019_658_Fig1_HTML.jpg

相似文献

1
Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059).接受选择性布鲁顿酪氨酸激酶抑制剂替拉布替尼（GS/ONO-4059）治疗的套细胞淋巴瘤（MCL）患者的长期随访
Leukemia. 2020 May;34(5):1458-1461. doi: 10.1038/s41375-019-0658-7. Epub 2019 Dec 11.
2
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.选择性布鲁顿酪氨酸激酶（BTK）抑制剂ONO/GS-4059用于复发和难治性成熟B细胞恶性肿瘤的1期临床试验。
Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5.
3
Novel therapies for relapsed/refractory mantle cell lymphoma.复发/难治性套细胞淋巴瘤的新型疗法。
Best Pract Res Clin Haematol. 2018 Mar;31(1):105-113. doi: 10.1016/j.beha.2017.10.010. Epub 2017 Nov 20.
4
Evaluation of second-generation Bruton's tyrosine kinase inhibitors for the treatment of mantle cell lymphoma.第二代布鲁顿酪氨酸激酶抑制剂治疗套细胞淋巴瘤的评估
J Oncol Pharm Pract. 2025 Mar;31(2):230-235. doi: 10.1177/10781552241232331. Epub 2024 Feb 14.
5
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.泽布替尼治疗复发/难治性套细胞淋巴瘤患者的疗效：一种选择性布鲁顿酪氨酸激酶抑制剂。
Clin Cancer Res. 2020 Aug 15;26(16):4216-4224. doi: 10.1158/1078-0432.CCR-19-3703. Epub 2020 May 27.
6
Ibrutinib for the treatment of mantle cell lymphoma.伊布替尼用于治疗套细胞淋巴瘤。
Expert Rev Hematol. 2014 Oct;7(5):521-31. doi: 10.1586/17474086.2014.951323. Epub 2014 Aug 27.
7
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma.探究 B 细胞信号通路：探寻治疗套细胞淋巴瘤的新疗法。
Sci Signal. 2019 Feb 5;12(567):eaat4105. doi: 10.1126/scisignal.aat4105.
8
Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes.套细胞淋巴瘤患者伊布替尼治疗失败后，不太可能对挽救性化疗有反应，且预后不良。
Ann Oncol. 2015 Jun;26(6):1175-1179. doi: 10.1093/annonc/mdv111. Epub 2015 Feb 23.
9
Ibrutinib for mantle cell lymphoma.伊布替尼治疗套细胞淋巴瘤。
Future Oncol. 2016 Feb;12(4):477-91. doi: 10.2217/fon.15.342. Epub 2016 Jan 13.
10
Transformed mantle cell lymphoma with additional triple-hit genotypes can be resistant to a Bruton tyrosine kinase inhibitor.具有额外三打击基因型的转化型套细胞淋巴瘤可能对布鲁顿酪氨酸激酶抑制剂耐药。
Blood. 2024 May 16;143(20):2106. doi: 10.1182/blood.2024023818.

引用本文的文献

1
Efficacy and safety of tirabrutinib monotherapy in relapsed or refractory B-cell lymphomas/leukemia: a meta-analysis.替拉布替尼单药治疗复发或难治性B细胞淋巴瘤/白血病的疗效和安全性：一项荟萃分析。
Front Pharmacol. 2025 Apr 1;16:1559056. doi: 10.3389/fphar.2025.1559056. eCollection 2025.
2
Monitoring of molecular responses to tirabrutinib in a cohort of exceptional responders with relapsed/refractory mantle cell lymphoma.对一组复发/难治性套细胞淋巴瘤的特殊反应者队列中替拉布替尼分子反应的监测。
EJHaem. 2024 Jun 24;5(4):896-899. doi: 10.1002/jha2.966. eCollection 2024 Aug.
3
New Means and Challenges in the Targeting of BTK.
BTK 靶向的新方法和新挑战
Clin Cancer Res. 2024 Jun 3;30(11):2333-2341. doi: 10.1158/1078-0432.CCR-23-0409.
4
Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.替拉鲁替尼的长期安全性特征：在复发或难治性 B 细胞恶性肿瘤患者中进行的一项日本 I 期研究的最终结果。
Int J Hematol. 2023 Apr;117(4):553-562. doi: 10.1007/s12185-022-03514-6. Epub 2022 Dec 28.
5
Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib.用替拉布替尼成功治疗抗髓鞘相关糖蛋白神经病。
Heliyon. 2022 Oct 5;8(10):e10928. doi: 10.1016/j.heliyon.2022.e10928. eCollection 2022 Oct.
6
Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution.布鲁顿酪氨酸激酶抑制剂在原发性中枢神经系统淋巴瘤中的抗肿瘤疗效及脑内分布评估
Transl Cancer Res. 2021 May;10(5):1975-1983. doi: 10.21037/tcr-21-50.
7
Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features.布鲁顿酪氨酸激酶抑制剂在 B 细胞恶性肿瘤中的应用及其特点。
Target Oncol. 2022 Jan;17(1):69-84. doi: 10.1007/s11523-021-00857-8. Epub 2021 Dec 14.
8
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease.布鲁顿酪氨酸激酶抑制剂导致的出血：对药物类型和疾病的依赖性
Cancers (Basel). 2021 Mar 4;13(5):1103. doi: 10.3390/cancers13051103.
9
Comparative Analysis of BTK Inhibitors and Mechanisms Underlying Adverse Effects.BTK抑制剂的比较分析及不良反应的潜在机制
Front Cell Dev Biol. 2021 Mar 11;9:630942. doi: 10.3389/fcell.2021.630942. eCollection 2021.
10
Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies.慢性淋巴细胞白血病的发病机制与新型治疗策略的开发。
J Clin Exp Hematop. 2020 Dec 15;60(4):146-158. doi: 10.3960/jslrt.20036. Epub 2020 Nov 4.